Medical Radiology and Radiation Safety. 2022. Vol. 67. № 5
DOI: 10.33266/1024-6177-2022-67-5-59-63
D.V. Kuzmichev1, Z.Z. Mamedli1, M.V. Chernih2, A.A. Tryakin3,
A.V. Polinovskiy1, V.A. Aliev1,N.A. Kozlov4, A.A. Aniskin1
NEOADJUVANT CHEMORADIOTHERAPY WITH CONSOLIDATION CHEMOTHERAPY IMPROVES THE SURVIVAL OF PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
1Department of Coloproctology of RCRC N.N. Blokhin, Moscow, Russia
2Department of Radiation Oncology of RCRC N.N. Blokhin, Moscow, Russia
3Department of Chemotherapy of RCRC N.N. Blokhin, Moscow, Russia
4Department of Pathological anatomy of human tumors of RCRC N.N. Blokhin, Moscow, Russia
Contact person: Dmitriy Vladimirovich Kuzmichev, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
Purpose: Consideration of the long-term three-year results of combined treatment of patients with locally advanced rectal cancer using preoperative chemoradiotherapy and consolidating chemotherapy.
Material and methods: Patients aged >18 with histologycally verified MRI-staged low and medium T3(CRM+)‒4N0‒2M0 rectal cancer were included. In the study group patients received neoadjuvant chemoradiotherapy 52‒56 Gy in 2 Gy fractions with capecitabine 850 mg/m2 per os two times a day and followed by 4 cycles in СapOx regimen. In the control group, similar chemoradiotherapy was performed without consolidating chemotherapy. The study group consisted of 105 patients, and the control group consisted of 99 patients. The median follow-up was
42.4 months.
Results: The full planned course of preoperative treatment was carried out in 201 (98.5 %) patients. Progression of the disease after the neoadjuvant therapy was not detected in any patient. A complete pathological response in the tumor was registered in 29 (15.1 %) patients, and a complete clinical response in 12 (6 %) patients. In the study and control groups, these indicators were (20 % vs. 10.3 %, p=0.04) and (9.5 % vs. 2 %, p=0.01), respectively. Local relapses in the study were registered in 18 (8.8 %) patients, and distant metastases in
53 (26 %) patients. In the study and control groups, local relapse and distant metastases developed in 4.8 % vs. 13.1 % (p=0.03) and
20 % vs. 32.3 % (p=0.04), respectively. The overall three-year survival rate in patients in the study group was 92.9 %, in the control group
79.7 % (HR 0.2, 95 % CI 0.03‒0.24, p=0.01). Three-year relapse-free survival in patients in the study group was 75.5 %, and in the control group 59.6 % (HR 0.2, 95 % CI 0.05‒0.32, p=0.01).
Conclusion: Up to date, the strategy of combined neoadjuvant treatment seems to be the most promising. With a high degree of probability, this approach in the treatment of patients with locally advanced rectal cancer may become a new standard of therapy with a similar treatment algorithm.
Keywords: locally advanced rectal cancer, consolidating chemotherapy, neoadjuvant chemoradiotherapy, pathomorphosis
For citation: Kuzmichev DV, Mamedli ZZ, Chernih MV, Tryakin AA, Polinovskiy AV, Aliev VA,Kozlov NA, Aniskin AA. Neoadjuvant Chemoradiotherapy with Consolidation Chemotherapy Improves the Survival of Patients with Locally Advanced Rectal Cancer. Medical Radiology and Radiation Safety. 2022;67(5):59–63. (In Russian). DOI: 10.33266/1024-6177-2022-67-5-59-63
References
1. Каприн А.Д. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М: МНИОИ им. П.А.Герцена, 2019. 249 с. [Kaprin A.D. Zlokachestvennyye Novoobrazovaniya v Rossii v 2018 Godu (Zabolevayemost i Smertnost) = Malignant Neoplasms in Russia in 2018 (Morbidity and Mortality). Moscow Publ., 2019 249 p.] (In Russ.).
2. Sauer R., Becker H., Hohenberger W., et al. German Rectal Cancer Study Group. Preoperative Versus Postoperative Chemoradiotherapy for Rectal Cancer.
N. Engl. J. Med. 2004;351:1731–1740.
3. Roh M.S., Colangelo L.H., O’Connell M.J., et al. Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients with Carcinoma of the Rectum: NSABP R-03. J. Clin. Oncol. 2009;27:5124–5130.
4. Sauer R., Liersch T., Merkel S., et al. Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial after a Median Follow-up of 11 Years. J. Clin. Oncol. 2012;30:1926–1933.
5. Breugom A.J., van den Broek C.B.M., van Gijn W., et al. The Value of Adjuvant Chemotherapy in Rectal Cancer Patients after Preoperative Radiotherapy or Chemotherapy Followed by Tme-Surgery: The Proctor/Script Study. Eur. J. Cancer. 2013;49;S1.
6. Cionini L., Sainato A., De Paoli A., et al. Final Results of Randomized Trial on Adjuvant Chemotherapy after Preoperative Chemoradiation in Rectal Cancer. Radiother Oncol. 2010;96:S113-S114.
7. Glynne-Jones R., Chau I. Neoadjuvant Therapy before Surgical Treatment. EJC Suppl. 2013;11;2:45–59.
8. Roeder F.,Meldolesi E.,Gerum S.,Valentini V.,Rödel C. Recent Advances in Chemo- Radiation Therapy for Rectal Cancer: a Comprehensive Review. Radiat. Oncol. 2020;15;1:262.
9. Dworak O., Keilholz L., Hoffmann A. Pathological Features of Rectal Cancer after Preoperative Radiochemotherapy. Int. J. Colorectal Dis. 1997;12;1:19-23.
10. São Julião G.P., Habr-Gama A., Vailati B.B., et al. Is Neoadjuvant Chemoradiation with Dose-Escalation and Consolidation Chemotherapy Sufficient to Increase Surgery-Free and Distant Metastases-Free Survival in Baseline cT3 Rectal Cancer? Eur. J. Surg. Oncol. 2018;44:93–99.
11. Ludmir E.B., Palta M., Willett C.G., Czito B.G. Total Neoadjuvant Therapy for Rectal Cancer: an Emerging Option. Cancer. 2017;123:1497–1506.
12. Marco M.R., Zhou L., Patil S., Marcet J.E., Varma M.G., Oommen S., et al. Consolidation mFOLFOX6 Chemotherapy after Chemoradiotherapy Improves Survival in Patients with Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. Dis. Colon Rectum. 2018;61;10:1146–1155.
13. Myerson R.J., Tan B., Hunt S., et al. Five Fractions of Radiation Therapy Followed by 4 Cycles of FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer. Int. J. Radiat. Oncol. Biol. Phys. 2014;88:829–836.
14. Markovina S., Youssef F., Roy A., et al. Improved Metastasis- and Disease-Free Survival with Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared with Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis. Int. J. Radiat. Oncol. Biol. Phys. 2017;99:417–426.
15. Bujko K., Wyrwicz L., Rutkowski A., et al. Polish Colorectal Study Group. Long-Course Oxaliplatin-Based Preoperative Chemoradiation Versus 5 × 5 Gy and Consolidation Chemotherapy for cT4 or Fixed cT3 Rectal Cancer: Results of a Randomized Phase III Study. Ann. Oncol. 2016;27:834–842.
16. Fokas E. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J. Clin. Oncol. 2019;37;34:3212-3222.
17. Garcia-Aguilar J., Smith D.D., Avila K., et al. Optimal Timing of Surgery after Chemoradiation for Advanced Rectal Cancer: Preliminary Results of a Multicenter, Nonrandomized Phase II Prospective Trial. Ann. Surg. 2011;254:97-102.
18. Hospers G., Bahadoer R.R., Dijkstra E.A., et al. Short Course Radiotherapy Followed by Chemotherapy before TME in Locally Advanced Rectal Cancer: the Randomized RAPIDO Trial (Abstract). J. Clin. Oncol. 2020;38:4006.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.06.2022. Accepted for publication: 25.08.2022.